Joshua Makower

Dr. Joshua Makower is the Founder and serves as Board Member and Executive Chairman at ExploraMed. He serves as Board Member at Foundry SING1. He is also a Co-Founder and serves as Board Member at Willow. He serves as the General Partner at New Enterprise Associates. He is a Board Member at SetPoint Medical. He has worked closely with NEA since his time as an EIR back in 1995 and recently joined full-time as a General Partner on NEA's healthcare team leading our MedTech/health tech practice. Notable transactions from the ExploraMed portfolio include Acclarent, acquired by J&J in 2009. EndoMatrix, acquired by C.R. Bard in 1997 and TransVascular, acquired by Medtronic in 2003. On-going ExploraMed/NEA ventures include NeoTract, Moximed, Nuelle and NC7. In addition to his role at NEA, He serves on the faculty of the Stanford University Medical School as a Consulting Professor of Medicine and is Co-Founder of Stanford's Biodesign Innovation Program. He currently serves on the board of directors for DOTS Devices, Intact Vascular, Eargo, ExploraMed, Intrinsic Therapeutics, NeoTract, Moximed, Nuelle and Coravin. He holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women's health, and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine and a bachelor's degree in Mechanical Engineering from MIT. He serves as Investment Advisor at Medical Technology Venture Partner. He also served as Board Member at Ceterix Orthopaedics.